KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Accumulated Expenses (2016 - 2025)

Neogenomics' Accumulated Expenses history spans 16 years, with the latest figure at $47.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 276.9% year-over-year to $47.6 million; the TTM value through Dec 2025 reached $47.6 million, up 276.9%, while the annual FY2025 figure was $47.6 million, 276.9% up from the prior year.
  • Accumulated Expenses reached $47.6 million in Q4 2025 per NEO's latest filing, up from $17.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $50.9 million in Q2 2024 to a low of $12.6 million in Q4 2024.
  • Average Accumulated Expenses over 5 years is $26.4 million, with a median of $20.8 million recorded in 2024.
  • The largest YoY upside for Accumulated Expenses was 276.9% in 2025 against a maximum downside of 63.68% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $17.8 million in 2021, then dropped by 15.32% to $15.1 million in 2022, then decreased by 0.01% to $15.1 million in 2023, then fell by 16.23% to $12.6 million in 2024, then skyrocketed by 276.9% to $47.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Accumulated Expenses are $47.6 million (Q4 2025), $17.4 million (Q3 2025), and $18.5 million (Q2 2025).